Oral field cancerization: Carcinogen-induced independent events or micrometastatic
Therefore, it is important to treat micrometastatic
disease with perioperative chemotherapy.
One third of remaining 50% with organ confined disease actually have micrometastatic
disease at time of surgery.
Patients with Stage II and III BC have a high risk of micrometastatic
sup] FXIII was found to be involved in tumor metastasis in the research of mice by limiting natural killer cell-mediated clearance of micrometastatic
Amended Diagnosis Discoverer Downgraded diagnoses 1 DCIS in sclerosing Pathologist adenosis 2 (a) DCIS in sclerosing Pathologist adenosis 3 DCIS in sclerosing Pathologist adenosis Upgraded diagnoses 4 IDC Pathologist 5 IDC, DCIS Pathologist 6 IDC, DCIS Pathologist 7 DCIS with Pathologist microinvasion 8 Microinvasive Pathologist lobular carcinoma 9 IDC, DCIS Pathologist 10 Micrometastatic
Pathologist carcinoma Changed diagnoses 11 ADH in complex Pathologist sclerosing lesion 12 Severe ADH Pathologist 13 DLBCL Pathologist 14 Amyloidoma Pathologist Mechanism of Time to Case No.
4% of those detected by IHC) had micrometastatic
disease, ranging from 0.
1,2) This combination addresses the loco-regional pelvic disease and the systemic micrometastatic
Presence of micrometastatic
tumor cells in the liver may induce the Kupffer cells to produce a variety of cytokines (IL-1, IL-6, and TNF-a), which may modulate albumin synthesis by hepatocytes [1, 2].
Identification of a serum-detectable metabolomic fingerprint potentially correlated with the presence of micrometastatic
disease in early breast cancer patients at varying risks of disease relapse by traditional prognostic methods.
The fact that the mutation was detected some 14 years after the patient was successfully treated for local recurrence suggests persistence of a dormant micrometastatic
clone, as was suggested by our previous Affymetrix SNP 6.
According to Galena Biopharma, the nelipepimut-S sequence stimulates specific CD8+ cytotoxic T lymphocytes (CTLs) after binding to HLA-A2/A3 molecules on antigen presenting cells and the activated specific CTLs recognise, neutralise and destroy, through cell lysis, HER2 expressing cancer cells, including occult cancer cells and micrometastatic